Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder
Status:
Completed
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about impact of extracorporeal electromagnetic
stimulation in addition to medical treatment with mirabegron on the treatment of overactive
bladder (OAB). The study will include female patients, aged between 30 and 80, with signs of
OAB, including urinary frequency, urgency and urinary urgency incontinence.
The main questions it aims to answer are:
- Does the addition of extracorporeal electromagnetic stimulation to medical treatment
with mirabegron influence the urinary urgency incontinent or frequency?
- Does the addition of extracorporeal electromagnetic stimulation to medical treatment
with mirabegron influence the urine flow or post-void residual volume?
- Does the addition of extracorporeal electromagnetic stimulation to medical treatment
with mirabegron influence the patients' quality of life.
Participants will:
- receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB
according to current treatment guidelines.
- Twice a week receive extracorporeal electromagnetic stimulation in the duration of 20
minutes. The patients will be divided into 2 groups, namely one group will receive
actual electromagnetic stimulation, and the other group will receive placebo
stimulation.
- Have a urogynecological examination, with ultrasound measurements of the remaining urine
in the bladder and determination of the thickness of the bladder wall, as well as a
uroflow examination, after 4 and 8 weeks of treatment.
- Have to to submit urine for laboratory tests and to fill out questionnaires regarding
participants' symptoms, after 4 and 8 weeks of treatment.
Researchers will compare both study groups to see if the addition of extracorporeal
electromagnetic stimulation has influence on the research questions stated above.